日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

高选择性、非共价(可逆) BTK 抑制剂吡托布替尼的临床前表征

Eliana B Gomez, Kevin Ebata, Hetal S Randeria, Mary S Rosendahl, E Peder Cedervall, Tony H Morales, Lauren M Hanson, Nicholas E Brown, Xueqian Gong, Jennifer Stephens, Wenjuan Wu, Isabel Lippincott, Karin S Ku, Richard A Walgren, Paolo B Abada, Joshua A Ballard, Charles K Allerston, Barbara J Brandh

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

RET 溶剂前沿突变介导 RET 驱动的恶性肿瘤对选择性 RET 抑制产生获得性耐药性

Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist, Geoffrey R Oxnard, Oliver Gautschi, Alexander Drilon, Vivek Subbiah, Christine Khoo, Edward Y Zhu, Michele Nguyen, Dahlia Henry, Kevin R Con

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

通过聚合性 MAPK 通路激活介导对 TRK 抑制的抵抗

Emiliano Cocco #, Alison M Schram #, Amanda Kulick, Sandra Misale, Helen H Won, Rona Yaeger, Pedram Razavi, Ryan Ptashkin, Jaclyn F Hechtman, Eneda Toska, James Cownie, Romel Somwar, Sophie Shifman, Marissa Mattar, S Duygu Selçuklu, Aliaksandra Samoila, Sean Guzman, Brian B Tuch, Kevin Ebata, Elisa